A detailed history of Victory Capital Management Inc transactions in Nuvalent, Inc. stock. As of the latest transaction made, Victory Capital Management Inc holds 150,199 shares of NUVL stock, worth $13.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
150,199
Previous 172,629 12.99%
Holding current value
$13.7 Million
Previous $13.1 Million 17.33%
% of portfolio
0.02%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$67.44 - $112.17 $1.51 Million - $2.52 Million
-22,430 Reduced 12.99%
150,199 $15.4 Million
Q2 2024

Aug 05, 2024

SELL
$62.76 - $81.61 $226,940 - $295,101
-3,616 Reduced 2.05%
172,629 $13.1 Million
Q1 2024

May 03, 2024

SELL
$72.35 - $88.99 $642,178 - $789,875
-8,876 Reduced 4.79%
176,245 $13.2 Million
Q4 2023

Feb 05, 2024

SELL
$42.42 - $80.28 $1.01 Million - $1.91 Million
-23,853 Reduced 11.41%
185,121 $13.6 Million
Q3 2023

Nov 06, 2023

BUY
$39.12 - $49.85 $7.11 Million - $9.06 Million
181,741 Added 667.36%
208,974 $9.61 Million
Q2 2023

Jul 27, 2023

SELL
$23.58 - $44.68 $126,789 - $240,244
-5,377 Reduced 16.49%
27,233 $1.15 Million
Q1 2023

May 02, 2023

SELL
$25.42 - $33.52 $1.05 Million - $1.39 Million
-41,440 Reduced 55.96%
32,610 $850,000
Q4 2022

Feb 09, 2023

BUY
$18.46 - $36.37 $222,812 - $438,985
12,070 Added 19.47%
74,050 $2.21 Million
Q3 2022

Nov 02, 2022

SELL
$13.55 - $19.92 $21,951 - $32,270
-1,620 Reduced 2.55%
61,980 $1.21 Million
Q1 2022

May 04, 2022

SELL
$11.65 - $19.57 $49,279 - $82,781
-4,230 Reduced 6.24%
63,600 $883,000
Q4 2021

Feb 07, 2022

BUY
$18.01 - $30.1 $506,081 - $845,810
28,100 Added 70.73%
67,830 $1.29 Million
Q3 2021

Nov 02, 2021

BUY
$18.25 - $38.35 $725,072 - $1.52 Million
39,730 New
39,730 $896,000

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $3.92B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.